Contributions
Abstract: EP1701
Type: ePoster
Abstract Category: Therapy - disease modifying - 28 Long-term treatment monitoring
Background: Alemtuzumab is approved in Canada for the treatment of adult patients with RRMS with active disease as defined by clinical and imaging features, and an inadequate response to interferon-β or other disease-modifying therapies (DMTs). In the CARE-MS II study (NCT00548405), alemtuzumab (12 mg/day IV; 5 consecutive days at baseline, 3 consecutive days 12 months later) significantly improved clinical and MRI outcomes vs SC IFNB-1a (44 µg; 3 times weekly) in patients with active RRMS who had an inadequate response to prior therapy.
Goal: To describe real-world evidence (RWE) demographic and clinical characteristics of patients treated with alemtuzumab in clinical practice in Canada relative to the CARE-MS II study population.
Methods: MS One-to-One is a patient support program for patients with RRMS, facilitating access to alemtuzumab and ensuring monitoring during treatment. In this retrospective, descriptive analysis, demographic and clinical characteristics of real-world Canadian patients, who were previously treated with other DMT(s) and who received alemtuzumab between 1 Jan 2014 and 1 May 2017, were assessed and compared with baseline characteristics of patients who participated in CARE-MS II. Consent was provided by neurologists and patients for the use of all clinical information from MS One-to-One.
Results: A total of 494 patients were enrolled in the Canadian MS One-to-One program and had received at least 1 course of alemtuzumab and ≥1 prior DMT. Of these, 33.0% had been treated with 1 prior DMT, 30.2% had 2 prior DMTs, and 36.8% had >2 prior DMTs. The majority of patients were switched from either fingolimod (32.6%), dimethyl fumarate (22.5%), natalizumab (19.8%), or glatiramer acetate (13.4%). Reasons for switching included lack of effectiveness (45.7%), tolerability (17.2%), and physician choice (7.5%). In comparison to the CARE-MS II population at study baseline, the Canadian real-world alemtuzumab-treated patient population was older (38.9 years [y] vs 34.8 y), included a greater percentage of females (74% vs 66%), had a longer duration of disease (8.0 y vs 4.5 y), and had a similar mean EDSS score at baseline (3.0 vs 2.7).
Conclusion: This analysis represents RWE of previously treated patients receiving alemtuzumab in Canada. As RWE is gained, the use and sequencing of alemtuzumab may evolve.
Study support: Sanofi.
Disclosure:
AS, LH, EP, and AG: Employees of Sanofi.
Abstract: EP1701
Type: ePoster
Abstract Category: Therapy - disease modifying - 28 Long-term treatment monitoring
Background: Alemtuzumab is approved in Canada for the treatment of adult patients with RRMS with active disease as defined by clinical and imaging features, and an inadequate response to interferon-β or other disease-modifying therapies (DMTs). In the CARE-MS II study (NCT00548405), alemtuzumab (12 mg/day IV; 5 consecutive days at baseline, 3 consecutive days 12 months later) significantly improved clinical and MRI outcomes vs SC IFNB-1a (44 µg; 3 times weekly) in patients with active RRMS who had an inadequate response to prior therapy.
Goal: To describe real-world evidence (RWE) demographic and clinical characteristics of patients treated with alemtuzumab in clinical practice in Canada relative to the CARE-MS II study population.
Methods: MS One-to-One is a patient support program for patients with RRMS, facilitating access to alemtuzumab and ensuring monitoring during treatment. In this retrospective, descriptive analysis, demographic and clinical characteristics of real-world Canadian patients, who were previously treated with other DMT(s) and who received alemtuzumab between 1 Jan 2014 and 1 May 2017, were assessed and compared with baseline characteristics of patients who participated in CARE-MS II. Consent was provided by neurologists and patients for the use of all clinical information from MS One-to-One.
Results: A total of 494 patients were enrolled in the Canadian MS One-to-One program and had received at least 1 course of alemtuzumab and ≥1 prior DMT. Of these, 33.0% had been treated with 1 prior DMT, 30.2% had 2 prior DMTs, and 36.8% had >2 prior DMTs. The majority of patients were switched from either fingolimod (32.6%), dimethyl fumarate (22.5%), natalizumab (19.8%), or glatiramer acetate (13.4%). Reasons for switching included lack of effectiveness (45.7%), tolerability (17.2%), and physician choice (7.5%). In comparison to the CARE-MS II population at study baseline, the Canadian real-world alemtuzumab-treated patient population was older (38.9 years [y] vs 34.8 y), included a greater percentage of females (74% vs 66%), had a longer duration of disease (8.0 y vs 4.5 y), and had a similar mean EDSS score at baseline (3.0 vs 2.7).
Conclusion: This analysis represents RWE of previously treated patients receiving alemtuzumab in Canada. As RWE is gained, the use and sequencing of alemtuzumab may evolve.
Study support: Sanofi.
Disclosure:
AS, LH, EP, and AG: Employees of Sanofi.